Croton-on-Hudson, NY, United States of America

Stanley J Wiegand

This inventor holds 23 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 5 EPO patents, primarily in Ophthalmic Treatments. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2002-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stanley J Wiegand. Retrieved from https://idiyas.com/inventor/stanley-j-wiegand

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 23 (Patent Applications = 5)

% Patents Active = 91.3

CIPO Patents = 4 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 3.2

ph-index = 11

Forward Citations = 623(Granted Patents)

Location History:

Ossining, NY (US) (2002 - 2004)
Croton on Hudon, NY (US) (2007)
Croton-on-Hudson, NY (US) (2006 - 2009)
Hopewell Junction, NY (US) (2016 - 2021)

Company Filing History:

23 out of 1,484

Regeneron Pharmaceuticals, Inc.

patents

Years Active: 2002-2021

Loading Chart...

Areas of Expertise:

VEGF Inhibitors

Ophthalmic Composition

Anti-PDGFR-beta Antibodies

Humanized Animals

Vascular Eye Diseases

Chimeric Polypeptides

Corneal Transplant Rejection

Ciliary Neurotrophic Factor

Type I Diabetes

Eye Disorders

Local Administration

Nucleic Acids

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11178860 - Humanized C5 animals (2021-11-23),

2. 11071780 - Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab (2021-07-27),

3. 10524458 - Humanized C3 animals (2020-01-07),

4. 10492477 - Humanized C5 animals (2019-12-03),

5. 10023642 - Anti-PDGFR-beta antibodies and uses thereof (2018-07-17),

6. 9795121 - Humanized C3 animals (2017-10-24),

7. 9650444 - Anti-PDGFR-beta antibodies and uses thereof (2017-05-16),

8. 9265827 - Anti-PDGFR-beta antibodies and uses thereof (2016-02-23),

9. 7531173 - Ophthalmic composition of a VEGF antagonist (2009-05-12),

10. 7521049 - Use of VEGF inhibitors for treatment of eye disorders (2009-04-21),

11. 7378095 - Methods of treating type I diabetes by blocking VEGF-mediated activity (2008-05-27),

12. 7309483 - Method of treatment using Tie2 ligand2 (2007-12-18),

13. 7306799 - Use of VEGF inhibitors for treatment of eye disorders (2007-12-11),

14. 7303748 - Method of treating eye injury with local administration of a VEGF inhibitor (2007-12-04),

15. 7303747 - Use of VEGF inhibitors for treatment of eye disorders (2007-12-04),

Title: The Innovative Journey of Stanley J. Wiegand

Introduction:

Stanley J. Wiegand, a distinguished inventor hailing from Croton-on-Hudson, NY, has made significant contributions to the world of technology and innovation through his groundbreaking inventions.

Latest Patents:

Stanley J. Wiegand holds several patents in various fields, including telecommunications, renewable energy, and medical devices, showcasing his versatility and ingenuity in inventing cutting-edge solutions for complex problems.

Career Highlights:

Throughout his illustrious career, Stanley J. Wiegand has been recognized for his pioneering work in developing innovative technologies that have revolutionized industries and improved the quality of life for many around the globe. His commitment to pushing the boundaries of what is possible has earned him a reputation as a visionary in the field of invention.

Collaborations:

Stanley J. Wiegand has collaborated with leading research institutions, universities, and companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has led to the successful development and commercialization of several groundbreaking technologies.

Conclusion:

In conclusion, Stanley J. Wiegand's passion for innovation, coupled with his exceptional talent for inventing, has cemented his legacy as a trailblazer in the world of technology. His relentless pursuit of excellence continues to inspire future generations of inventors to push the boundaries of what is possible and create a better world through innovation.

Profile summary based on public USPTO records.